Surunkali yurak yetishmovchiligi bilan kasallangan kasallarni davolashda SGLT 2 ingibitorlarining roli.
PDF
DOI

Keywords

Surunkali yurak yetishmovchiligi, qandli diabet, SGLT 2 ingibitori, renin angiotenzin sistemasi, miokard infarkti.

How to Cite

Surunkali yurak yetishmovchiligi bilan kasallangan kasallarni davolashda SGLT 2 ingibitorlarining roli. (2023). Journal of Universal Science Research, 1(9), 334-340. https://universalpublishings.com/index.php/jusr/article/view/1999

Abstract

Natriy-glyukoza ko-transporterlari-2 (SGLT2 ) surunkali yurak yetishmovchiligi bilan kasallangan bemorlarni davolashdagi nisbatan yangi guruh dori vositalaridan hisoblanadi. Bu guruh dori moddalariga empagliflozin, dapagliflozin, sotagliflozin, ertugliflozin kabi dori vositalari kiradi. Bu dori vositalarining asosiy ta’sir mexanizmi buyrakning proksimal naychalaridan glyukoza so’rilishini kamaytirish hisoblanadi. SGLT2 ingibitorlari gipoglikemik dori vosita sifatida 2-tip Qandli diabet bilan kasallangan bemorlarni davolashda qo’llaniladi. Glyukoza so’rilishini kamaytirish bilan birgalikda miokard infarkti, insult va yurak qon tomir kasalliklaridan o’lim xavfini kamaytiradi. SGLT2 ingibitorlarining bir qancha ta’sir mexanizmi aniqlangan bo’lishiga qaramasdan aynan qanday mexanizm orqali yurak qon tomir kasalliklaridan o’lim xavfini kamaytirishi no’malumligicha qolmoqda. Biroq shu kungacha o’tkazilgan tadqiqotlar shuni ko’rsatmoqdaki SGLT2 ingibitorlari   surunkali yurak yetishmovchiligining barcha bosqichlarida 1 A ko’rsatma sifatida qo’llash mumkin.

PDF
DOI

References

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW and Turner MB. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133:e38-360.

WHO. Global Report on Diabetes. 2016; http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1, Accessed December 20, 2016.

Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S and Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765-72.

Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB and Danesh J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. The New England journal of medicine. 2011;364:829- 41.

Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Jr. and Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-46.

Komajda M, Tavazzi L, Francq BG, Bohm M, Borer JS, Ford I and Swedberg K. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail. 2015;17:1294-301.

Fitchett DH, Udell JA and Inzucchi SE. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail. 2017;19:43-53.

ESC Guidelines 2023. Recommendation for chronic and acute heart failure.

Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ and Levy D. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-72.

Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, Stevenson JC and Coats AJ. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30:527-32.

Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL and Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. The New England journal of medicine. 2006;355:251-9.

Zhou L, Deng W, Zhou L, Fang P, He D, Zhang W, Liu K and Hu R. Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review. Curr Diabetes Rev. 2009;5:171-84.

Dinesh Shah A, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A and Hemingway H. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1.9 million people. Lancet. 2015;385 Suppl 1:S86.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.